Recent Updates
Recently added Catalysts
CTNM Positive Sentiment

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

Thursday, May 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of a brain-penetrant small molecule antagonist that targets LPA1 receptors. This compound shows promise in reducing neuroinflammation and promoting remyelination in multiple sclerosis. The findings could lead to new therapeutic strategies for managing MS symptoms and improving patient outcomes.
Price reaction · baseline $15.69 (2024-05-08 close) · hit pre-market · clean, no other CTNM news in the window
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of a new small molecule antagonist targeting LPA1 receptors.
  • Potential to reduce neuroinflammation in multiple sclerosis.
  • Promotes remyelination, which is crucial for MS treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
6.4%
average across 3 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
PIPE-307 Dose A
Phase 2 · Relapsing Remitting Multiple Sclerosis

Full Press Release Details

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen & Daniel S. Lorrain
Scientific Reports

Frequently Asked Questions

What is the significance of the LPA1 receptor antagonist?

The LPA1 receptor antagonist may help reduce neuroinflammation and promote remyelination in multiple sclerosis.

How does the small molecule antagonist work?

It targets LPA1 receptors in the brain, potentially improving outcomes for MS patients.

What condition is this research focused on?

The research focuses on multiple sclerosis and its associated neuroinflammation.

Who conducted the research on the LPA1 antagonist?

The study was conducted by a team of researchers including Michael M. Poon and others.

ShareAdd on Google
Tags: CTNM Viatris Investor Conferences Healthcare LPA1 receptors neuroinflammation remyelination multiple sclerosis small molecule
Last updated: May 9, 2024

Biotech snapshot

Cash runway
$237M liquidity · $4M/mo burn
~61 mo
Minimal dilution risk
Lead asset
PIPE-307 Dose APhase 2
Relapsing Remitting Multiple Sclerosis →

Catalyst track record

+79%
best trade around CTNM's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CTNM.

See every catalyst's timing & PoA →